Osteoporosis is a disease in which bone density is decreased and fractures occur easily due to external environment. The treatment of osteoporosis is important to prevent bone loss and to suppress the formation of osteoclasts involved in bone resorption. Osteoclasts, which are multinucleated cells, are greatly increased and overactivated in bone diseases including osteoporosis and rheumatoid arthritis. In this study, the effect of savinin on osteoclast differentiation by RANKL was investigated. Savinin significantly inhibited RANKL-induced osteoclast differentiation by inhibiting the transcriptional and translational expression of NFATc1, an essential component of RANKL-mediated osteoclast formation. In addition, mRNA expressions of OSCAR, DC-STAMP, and CTSK related to osteoclast differentiation and function were suppressed. Inhibition of osteoclast activity was verified through bone resorptive assay. Therefore, it is confirmed that savinin inhibits osteoclast differentiation, so it has the potential to be used as a therapeutic agent for the treatment of osteoporosis.
Conflict of Interest